Skip to Main Content

When doctors prescribe a personalized cell therapy today, the patient they’re trying to help has blood cancer so advanced other medicines no longer work. In the future, these so-called CAR-T treatments might be used earlier, for greater benefit, when cancer patients aren’t so desperately sick.

Toward that goal, a CAR-T therapy called cilta-cel from Johnson & Johnson was more effective and better tolerated when used to treat patients with less advanced multiple myeloma, according to preliminary study results released Wednesday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!